Mirum Pharmaceuticals Expands LIVMARLI Approval and Acquires Bluejay Therapeutics for Rare Liver Diseases

Health Canada has authorized LIVMARLI for pediatric patients with PFIC and Alagille syndrome, expanding treatment options for children with rare liver diseases. Mirum Pharmaceuticals, which acquired Bluejay Therapeutics, has a late-stage hepatitis D program, adding to its rare disease portfolio. The company's focus on rare liver diseases and potential expansion of its addressable market through new indications make it an attractive investment for long-term investors.